Immix Biopharma Inc
$ 10.06
5.45%
06 Aug - close price
- Market Cap 679,152,000 USD
- Current Price $ 10.06
- High / Low $ 10.10 / 9.52
- Stock P/E N/A
- Book Value 1.59
- EPS -0.92
- Next Earning Report 2026-08-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.39 %
- ROE -0.74 %
- 52 Week High 12.14
- 52 Week Low 1.94
About
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United States and Australia. The company is headquartered in Los Angeles, California.
Analyst Target Price
$19.91
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-25 | 2025-11-07 | 2025-08-08 | 2025-05-08 | 2025-03-24 | 2024-11-12 | 2024-08-12 | 2024-05-09 | 2024-03-29 | 2023-11-09 | 2023-08-11 |
| Reported EPS | -0.18 | -0.28 | -0.24 | -0.22 | -0.15 | -0.25 | -0.24 | -0.15 | -0.22 | -0.23 | -0.23 | -0.24 |
| Estimated EPS | -0.21 | -0.15 | -0.19 | -0.16 | -0.23 | -0.25 | -0.16 | -0.21 | -0.23 | -0.23 | -0.23 | -0.17 |
| Surprise | 0.03 | -0.13 | -0.05 | -0.06 | 0.08 | 0 | -0.08 | 0.06 | 0.01 | 0 | 0 | -0.07 |
| Surprise Percentage | 14.2857% | -86.6667% | -26.3158% | -37.5% | 34.7826% | 0% | -50% | 28.5714% | 4.3478% | 0% | 0% | -41.1765% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-14 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IMMX
2026-08-07 02:41:52
Pomerantz LLP is investigating potential securities fraud claims against Immix Biopharma, Inc. (NASDAQ: IMMX) following a significant drop in its stock price. The investigation centers on the company's hiring and subsequent termination of a Chief Medical Officer who was later revealed to be a fugitive from a 2005 rape trial. Immix's stock fell 14.15% after this news came to light.
2026-08-07 00:41:52
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Immix Biopharma, Inc. (NASDAQ: IMMX) following revelations about the company's former Chief Medical Officer, Richard Graydon, who was allegedly a fugitive named Ronald L. Fischer. Fischer had disappeared during a rape trial in 2005 and was arrested in July 2026, causing Immix's share prices to drop by over 14.1%. SBS is inviting shareholders who suffered losses to participate in the fraud investigation.
2026-08-04 16:49:00
Pomerantz LLP is investigating Immix Biopharma, Inc. (NASDAQ: IMMX) following a significant stock price drop. This investigation comes after the company's former Chief Medical Officer, Richard Graydon (whose real name was Ronald L. Fischer), was arrested as a fugitive wanted since 2005 for a rape trial. The firm is looking into potential securities fraud or unlawful business practices by Immix officers and directors.
2026-08-04 13:39:45
Immix Biopharma (Nasdaq: IMMX) announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference from September 14-16, 2026, where it will host one-on-one investor meetings. The company will discuss its lead AL Amyloidosis CAR-T candidate, NXC-201, which has received FDA Breakthrough Therapy, RMAT, and Orphan Drug designations. Interested investors can request meetings through their Morgan Stanley representatives, and a replay link will be available on Immix Biopharma's website.
2026-08-04 13:21:03
Immix Biopharma (IMMX) announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference from September 14-16, 2026, where it will host meetings with institutional investors. The company, a leader in treating relapsed/refractory AL Amyloidosis, will discuss its lead CAR-T cell therapy, NXC-201, which has received multiple FDA designations including Breakthrough Therapy. Investors interested in meeting with ImmixBio are advised to contact their Morgan Stanley representatives.
2026-08-04 13:15:03
Immix Biopharma, Inc. (IMMX) announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference from September 14-16, 2026, where it will host institutional investor meetings. The company, a leader in relapsed/refractory AL Amyloidosis, will be available for one-on-one meetings. ImmixBio's lead candidate, NXC-201, a BCMA-targeted CAR-T cell therapy for AL Amyloidosis, is currently being evaluated in a U.S. multi-center study and has received Breakthrough Therapy Designation and Orphan Drug Designation.
